CN110585418A - External use disinfection essential oil emulsion for women and production process thereof - Google Patents
External use disinfection essential oil emulsion for women and production process thereof Download PDFInfo
- Publication number
- CN110585418A CN110585418A CN201810609051.2A CN201810609051A CN110585418A CN 110585418 A CN110585418 A CN 110585418A CN 201810609051 A CN201810609051 A CN 201810609051A CN 110585418 A CN110585418 A CN 110585418A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- parts
- female
- oil emulsion
- disinfectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 174
- 239000000839 emulsion Substances 0.000 title claims abstract description 56
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 238000004659 sterilization and disinfection Methods 0.000 title abstract description 8
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 16
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims abstract description 13
- 108010001478 Bacitracin Proteins 0.000 claims abstract description 13
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003071 bacitracin Drugs 0.000 claims abstract description 13
- 229930184125 bacitracin Natural products 0.000 claims abstract description 13
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims abstract description 13
- 229960002510 mandelic acid Drugs 0.000 claims abstract description 13
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 13
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 13
- 241000196324 Embryophyta Species 0.000 claims description 24
- 239000000645 desinfectant Substances 0.000 claims description 20
- 241000220317 Rosa Species 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 13
- 241000208422 Rhododendron Species 0.000 claims description 12
- 244000182022 Salvia sclarea Species 0.000 claims description 12
- 235000002911 Salvia sclarea Nutrition 0.000 claims description 12
- 240000007436 Cananga odorata Species 0.000 claims description 8
- 241000366182 Melaleuca alternifolia Species 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 235000003826 Artemisia Nutrition 0.000 claims description 6
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 6
- 241000378467 Melaleuca Species 0.000 claims description 6
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 6
- 244000030166 artemisia Species 0.000 claims description 6
- 235000009052 artemisia Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 235000013479 Amaranthus retroflexus Nutrition 0.000 claims description 5
- 244000055702 Amaranthus viridis Species 0.000 claims description 5
- 235000004135 Amaranthus viridis Nutrition 0.000 claims description 5
- 235000009344 Chenopodium album Nutrition 0.000 claims description 5
- 235000005484 Chenopodium berlandieri Nutrition 0.000 claims description 5
- 235000009332 Chenopodium rubrum Nutrition 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 230000002147 killing effect Effects 0.000 abstract description 30
- 210000001215 vagina Anatomy 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 16
- 241000186660 Lactobacillus Species 0.000 abstract description 11
- 244000052616 bacterial pathogen Species 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 229940039696 lactobacillus Drugs 0.000 abstract description 9
- 241000233866 Fungi Species 0.000 abstract description 8
- 241000223996 Toxoplasma Species 0.000 abstract description 8
- 241000700605 Viruses Species 0.000 abstract description 8
- 210000004291 uterus Anatomy 0.000 abstract description 8
- 210000001672 ovary Anatomy 0.000 abstract description 7
- 238000004140 cleaning Methods 0.000 abstract description 6
- 208000035473 Communicable disease Diseases 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 5
- 241001180364 Spirochaetes Species 0.000 abstract description 4
- 230000002378 acidificating effect Effects 0.000 abstract description 4
- 239000006041 probiotic Substances 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 241001502500 Trichomonadida Species 0.000 abstract description 3
- 239000007938 effervescent tablet Substances 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 15
- 201000008100 Vaginitis Diseases 0.000 description 13
- 206010046914 Vaginal infection Diseases 0.000 description 12
- 241000238631 Hexapoda Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 241000224526 Trichomonas Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 235000003069 Artemisia scoparia Nutrition 0.000 description 5
- 241001249148 Artemisia scoparia Species 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 5
- 235000007571 Cananga odorata Nutrition 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 5
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000007721 medicinal effect Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 241000589970 Spirochaetales Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- CYIFVRUOHKNECG-UHFFFAOYSA-N tridecan-2-one Chemical compound CCCCCCCCCCCC(C)=O CYIFVRUOHKNECG-UHFFFAOYSA-N 0.000 description 4
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 3
- 208000037009 Vaginitis bacterial Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 229930007744 linalool Natural products 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- IHPKGUQCSIINRJ-CSKARUKUSA-N (E)-beta-ocimene Chemical compound CC(C)=CC\C=C(/C)C=C IHPKGUQCSIINRJ-CSKARUKUSA-N 0.000 description 2
- CJPNOLIZCWDHJK-UHFFFAOYSA-N 2-Pentadecanone Chemical compound CCCCCCCCCCCCCC(C)=O CJPNOLIZCWDHJK-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021033 Hypomenorrhoea Diseases 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- IZWKTABKAJGBFW-UHFFFAOYSA-N arcapillin Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(OC)=C(OC)C(O)=C3C(=O)C=2)=C1O IZWKTABKAJGBFW-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- WYKWHSPRHPZRCR-UHFFFAOYSA-N eupatolitin Chemical compound OC=1C(=O)C=2C(O)=C(OC)C(OC)=CC=2OC=1C1=CC=C(O)C(O)=C1 WYKWHSPRHPZRCR-UHFFFAOYSA-N 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- HIGQPQRQIQDZMP-UHFFFAOYSA-N geranil acetate Natural products CC(C)=CCCC(C)=CCOC(C)=O HIGQPQRQIQDZMP-UHFFFAOYSA-N 0.000 description 2
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- CZCBTSFUTPZVKJ-UHFFFAOYSA-N rose oxide Chemical compound CC1CCOC(C=C(C)C)C1 CZCBTSFUTPZVKJ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UHEPJGULSIKKTP-UHFFFAOYSA-N sulcatone Chemical compound CC(C)=CCCC(C)=O UHEPJGULSIKKTP-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UHUFTBALEZWWIH-UHFFFAOYSA-N tetradecanal Chemical compound CCCCCCCCCCCCCC=O UHUFTBALEZWWIH-UHFFFAOYSA-N 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 239000001674 (E)-1-(2,6,6-trimethyl-1-cyclohexenyl)but-2-en-1-one Substances 0.000 description 1
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 description 1
- BGTBFNDXYDYBEY-UHFFFAOYSA-N 1-(2,6,6-trimethylcyclohexen-1-yl)but-2-en-1-one Chemical compound CC=CC(=O)C1=C(C)CCCC1(C)C BGTBFNDXYDYBEY-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- JZOCDHMHLGUPFI-UHFFFAOYSA-N 3,7-dimethylocta-1,6-dien-3-yl formate Chemical compound CC(C)=CCCC(C)(C=C)OC=O JZOCDHMHLGUPFI-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000723422 Catalpa Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- DZNVIZQPWLDQHI-UHFFFAOYSA-N Citronellyl formate Chemical compound O=COCCC(C)CCC=C(C)C DZNVIZQPWLDQHI-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- ZHPLPRUARZZBET-UHFFFAOYSA-N Gossypetin Natural products O1C2=C(O)C(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 ZHPLPRUARZZBET-UHFFFAOYSA-N 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- ZPFXBGIJKDANBP-UHFFFAOYSA-N Hibiscetin Natural products OC1=C(O)C(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C(O)=C3O2)O)=C1 ZPFXBGIJKDANBP-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- NRSUOHVIKLCXEE-UHFFFAOYSA-N Isorhamnetin 3-O-beta-D-glucopyranoside Natural products CCC1OC(OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(OC)c4)C(O)C(O)C1O NRSUOHVIKLCXEE-UHFFFAOYSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000217407 Margaritifera Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000219093 Rhamnus Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000002368 bacteriocinic effect Effects 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- POIARNZEYGURDG-UHFFFAOYSA-N beta-damascenone Natural products CC=CC(=O)C1=C(C)C=CCC1(C)C POIARNZEYGURDG-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003876 biosurfactant Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- -1 cirsicaritin Chemical compound 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- ARFAWNXJYKFWKI-UHFFFAOYSA-N eupatoranolide Natural products C12C=C(C)C(OC(C)=O)CC2C(C)CC2C1=C(C)C(=O)O2 ARFAWNXJYKFWKI-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- HNZUNIKWNYHEJJ-UHFFFAOYSA-N geranyl acetone Natural products CC(C)=CCCC(C)=CCCC(C)=O HNZUNIKWNYHEJJ-UHFFFAOYSA-N 0.000 description 1
- HNZUNIKWNYHEJJ-FMIVXFBMSA-N geranyl acetone Chemical compound CC(C)=CCC\C(C)=C\CCC(C)=O HNZUNIKWNYHEJJ-FMIVXFBMSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- YRRAGUMVDQQZIY-UHFFFAOYSA-N gossypetin Chemical compound C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(O)=C2O1 YRRAGUMVDQQZIY-UHFFFAOYSA-N 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- CQLRUIIRRZYHHS-LFXZADKFSA-N isorhamnetin 3-O-beta-D-glucopyranoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 CQLRUIIRRZYHHS-LFXZADKFSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- HIGQPQRQIQDZMP-FLIBITNWSA-N neryl acetate Chemical compound CC(C)=CCC\C(C)=C/COC(C)=O HIGQPQRQIQDZMP-FLIBITNWSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229930007790 rose oxide Natural products 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- OHEFFKYYKJVVOX-UHFFFAOYSA-N sulcatol Natural products CC(O)CCC=C(C)C OHEFFKYYKJVVOX-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- HGZHKWZIXPLKLY-UHFFFAOYSA-N tamarixetin 7-beta-D-glucopyranoside Natural products C1=C(O)C(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C=C2O1 HGZHKWZIXPLKLY-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940044950 vaginal gel Drugs 0.000 description 1
- 239000000029 vaginal gel Substances 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- IHPKGUQCSIINRJ-UHFFFAOYSA-N β-ocimene Natural products CC(C)=CCC=C(C)C=C IHPKGUQCSIINRJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of pharmaceuticals, in particular to an innovative external recuperation type disinfection essential oil emulsion medicament for women and a production process thereof, wherein the emulsion medicament comprises the following components in parts by weight: 2-40 parts of natural plant essential oil, 2-30 parts of bacitracin, 3-50 parts of mandelic acid, 10-55 parts of lactein and 8-50 parts of oligosaccharide prebiotics. The vaginal effervescent tablet has strong activity of inhibiting and killing pathogenic bacteria, fungi, spirochaetes, trichomonad, toxoplasma and viruses, can regulate and nourish the endogenous probiotics (lactobacillus) of the vagina, maintain the acidic environment of the vagina, has self-cleaning function and immunity, and nourish the tissue cells of the vagina, uterus and ovary, thereby preventing the occurrence of vaginal infectious diseases and preserving youth.
Description
Technical Field
The invention relates to the technical field of pharmaceuticals, in particular to female external disinfection essential oil emulsion and a production process thereof.
Background
Infectious vaginitis (bacterial vaginitis, mycotic vaginitis and trichomonas vaginitis), senile vaginitis, pruritus vulvae, leukoplakia vulvae and cervical erosion are common gynecological diseases, and common pathogenies of pathogenesis of the infectious vaginitis are vaginal microecological flora disorder, vaginal local immunity and resistance reduction, and inflammation of vagina, vulva and cervix is caused.
Microorganisms which do not have a harmful effect on the human body, commonly called normal microorganisms or normal flora, are colonized on the surface of the human body and in the cavity passages communicated with the outside. It is beneficial and harmless to human body, and is necessary. The female lower genital tract is an open cavity and is an important micro-ecological area in the human body, in the normal vaginal flora, lactobacillus is dominant, and per gram of vaginal secretion contains 107～108Lactobacillus CFU. More than 20 kinds of lactobacillus can be separated from vagina of healthy women. The normal presence of lactobacilli in the vagina plays a key role in maintaining a normal flora in the vagina. Glycogen in the vaginal squamous epithelial cells is decomposed into lactic acid under the action of lactobacillus, so that a weak acid environment (the pH is less than or equal to 4.5 and more than 3.8-4.4) is locally formed in the vagina, and the overgrowth of other parasitic bacteria can be inhibited. In addition, lactobacilli prevent pathogenic microorganisms from adhering to vaginal epithelial cells by alternative, competitive exclusion mechanisms. Meanwhile, the secretion of hydrogen peroxide, bacteriocin-like substance, biosurfactant and the like inhibits the growth of pathogenic microorganisms, thereby maintaining the balance of the vaginal micro-ecological environment and maintaining the health and youth of the female lower genital tract.
Large dose or long-term application of broad-spectrum antibacterial drugs, improper use of "systemic" disinfectants, poor hygiene habits and dirty transmission are important external causes of vaginal microecological flora imbalance; in the aspect of internal factors of an organism, in the premenstrual period and the gestation period of female married in middle and young adults, due to the fact that the vaginal estrogen level is increased, the glycogen level in vagina epithelium is increased, mycotic vaginitis and bacterial vaginosis are easily induced, senile vaginitis is mostly occurred in women after menopause, due to the fact that the ovary function of the female in the age period is degraded, the estrogen level in the body is reduced, the pH value of the local part of the vagina is increased (pH is 5.8-6.8), and therefore beneficial flora in vaginal microecological bacteria is reduced, the self-cleaning effect of the vagina is reduced, and atrophic vaginitis is caused.
The diseases are characterized by repeated attack in clinic, and a certain proportion of patients have no subjective discomfort symptoms, but the clinical consequences are serious, especially repeated attack or chronic bacterial vaginosis, cervicitis, oviduct and ovary infection, pelvic inflammation and the like are easy to cause, and the diseases are common reasons for female fertility loss.
In conclusion, female yin diseases are common diseases and frequently encountered diseases which seriously affect the physical and mental health of women. Therefore, effective prevention and treatment of various vaginitis is one of the important subjects in the medical field at home and abroad. At present, preparations (suppository, lotion, effervescent tablets, capsules, powder, cream, spray and the like) developed in China for preventing and treating various vaginitis reach more than one hundred kinds, and metronidazole or tinidazole is a well-known effective treatment agent for trichomonas vaginitis and bacterial vaginosis in various circulating prevention and treatment agents at present, but the side effects of the metronidazole or the tinidazole are increasingly concerned. Generally, about 10-20% of people who take the medicine for one time suffer from nausea and abnormal taste, and are very easy to cause mycotic vaginitis and superinfection after long-term taking, wherein 6-8% and 26% of patients suffer from mycotic vaginitis and damage to nervous systems when the medicine is taken for 2 days and 7 days respectively, and severe consequences such as habitual abortion, dead fetus and the like can also occur in local or systemic treatment in pregnancy. Imidazoles (such as ketoconazole, econazole, fluconazole, clotrimazole and the like) and polyenes (such as amphotericin B, nystatin and the like) are effective medicaments for treating mycotic vaginitis at present, but the toxic and side effects and high recurrence rate after treatment are also acknowledged.
Chinese invention patent CN106880698A discloses a plant essential oil for treating infantile vaginitis and a preparation method thereof, wherein the plant essential oil comprises the following components in parts by mass: fully and uniformly mixing grapefruit essential oil, tea tree essential oil, mint essential oil and rose essential oil to obtain a mixed solution A for later use, preparing a traditional Chinese medicine compound ethanol solution as a phase B, adding the phase A into the phase B, and fully and uniformly mixing to obtain a finished product; the Chinese medicinal compound ethanol solution comprises radix Et rhizoma Rhei, rhizoma Acori Calami, Polyporus, Concha Margaritifera, and fructus Perillae.
The technical scheme adopts the mild essential oil and Chinese medicinal compound combined medicine to realize the effect of treating the vaginitis. The sterilization rate to pathogenic bacteria such as bacillus, staphylococcus aureus, candida, fungi and the like is more than 99 percent; has obvious effects of removing peculiar smell and relieving itching; the long-term use of the vaginal gel does not change the acid-base balance in the vagina, has no drug resistance and no toxic or side effect, and has only slight stimulation on the vaginal mucosa; however, the killing power to protozoa such as trichomonas is very small, so that the treatment effect on trichomonas vaginitis needs to be improved.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide an innovative female external ecological recuperation type sterilized essential oil emulsion which has strong activities of inhibiting and killing pathogenic bacteria, fungi, spirochetes, trichomonads, toxoplasma and viruses.
The technical purpose of the invention is realized by the following technical scheme: a topical disinfectant essential oil emulsion for female comprises natural plant essential oil, bacitracin, mandelic acid, lactein, oligosaccharide prebiotics; wherein the natural plant essential oil comprises one or more of rhododendron anthopogonoides essential oil, clary sage essential oil, melaleuca viridis essential oil, and artemisia pigweed essential oil.
By adopting the technical scheme, the bacitracin has bactericidal effect on pathogenic gram-positive bacteria, pathogenic gram-negative cocci, pathogenic gram-negative spirochetes and the like;
the mandelic acid applied to the invention has strong activity of killing protozoa such as trichomonas, toxoplasma and the like, and greatly improves the treatment effect on trichomonas vaginitis;
the lactobacillin can form a weak acid environment (pH is less than or equal to 4.5) locally in the vagina, can inhibit the overgrowth of other parasitic bacteria and pathogenic bacteria, the proliferation efficiency of the oligosaccharide prebiotics to endogenous lactobacillin can reach 10-100 times higher, the prebiotics are indigestible saccharides without any toxic or side effect on human bodies, and the lactobacillin and the prebiotics have obvious 'nourishing and benefiting effects' as a microecological regulator.
The natural plant essential oil has extremely small molecules and high permeability, can be effectively absorbed through mucosa, contains rich functional components, and further improves the medicinal effect of the invention.
The Rhododendron anthopogonoides essential oil contains gossypetin and quercetin-gossypetin mixture, and has growth inhibiting effect on Diplococcus pneumoniae, Streptococcus A, Catalpa, Staphylococcus aureus and Staphylococcus albus.
The clary sage essential oil contains plant female hormone, is a good tonic for balancing vagina, uterus and hormone, is extremely beneficial to female reproductive systems, is extremely helpful to climacteric problems, especially frequent sweat, and can also treat vaginal candida infection; taking care of uterus and vagina, relieving premenstrual syndrome, regulating dysmenorrhea and hypomenorrhea, promoting menstrual cycle regularity, and promoting female charm and delaying aging after long-term use.
The melaleuca viridis essential oil is also called Gorman oil, is called as the skin and mucosa guard spirit, contains terpinene-4-ol, linalool, sesquiterpene, monoterpene alcohol and other components, has the effects of resisting virus, infection, inflammation and allergy, and is very beneficial to treating tonsillitis, herpes virus, viral enteritis, viral hepatitis, vaginitis, urinary tract infection and the like.
The essential oil contains 13 kinds of flavone and coumarin, including Arcapillin, Eupatolitin, isorhamnetin-3-glucoside, hyperin, cirsicaritin, isorhamnetin, quercetin, rhamnus senescens, dimethyl aesculus resin, capillaris, 4' -methyl capillaris, 7-methyl capillaris, Chinese thistle alcohol, etc. Has different degrees of inhibiting effects on staphylococcus aureus, diphtheria bacillus, anthrax bacillus, typhoid bacillus, paratyphoid bacillus A, pseudomonas aeruginosa, escherichia coli, shigella flexneri, shigella, diplococcus meningitidis, bacillus subtilis and the like; 1: 100 of the concentration has the inhibiting effect on both human type and bovine type tubercle bacillus, has strong inhibiting effect on fungi, and also has the inhibiting and killing effect on various leptospira.
The essential oil emulsion has the effects of inhibiting and killing pathogenic gram-positive bacteria, negative coccus, mycete, spirochete, virus and the like in vagina, has good compatibility of all components, is favorable for improving the treatment effect of the invention, and has no obvious side effect. Can also regulate dysmenorrhea and hypomenorrhea, and promote menstrual cycle regularity.
The invention is further configured to: comprises the following components in parts by weight:
2-40 parts of natural plant essential oil
Bacitracin 2-30 parts
3-50 parts of mandelic acid
10-55 parts of lactein
8-50 parts of oligosaccharide prebiotics.
By adopting the technical scheme, the medicinal effect is better by adopting the weight ratio, each component can play an obvious role, the medicine has very strong activity of inhibiting and killing pathogenic bacteria, fungi, spirochaetes, trichomonas, toxoplasma and viruses, can adjust the activity of endogenous probiotics (lactobacillus) of the Yin tract, maintain the acidic environment of the vagina, has a self-cleaning function and immunity, and nourishes the tissue cells of the vagina, the uterus and the ovary, thereby preventing the occurrence of vagina infectious diseases.
The invention is further configured to: comprises the following components in parts by weight:
2-30 parts of natural plant essential oil
Bacitracin 2-30 parts
3-50 parts of mandelic acid
10-55 parts of lactein
And 8-20 parts of oligosaccharide prebiotics.
By adopting the technical scheme, the medicinal effect is better by adopting the weight ratio, each component can play an obvious role, the medicine has very strong activity of inhibiting and killing pathogenic bacteria, fungi, spirochaetes, trichomonas, toxoplasma and viruses, can adjust the activity of endogenous probiotics (lactobacillus) of the Yin tract, maintain the acidic environment of the vagina, has a self-cleaning function and immunity, and nourishes the tissue cells of the vagina, the uterus and the ovary, thereby preventing the occurrence of vagina infectious diseases.
The invention is further configured to: comprises the following components in parts by weight:
2-40 parts of natural plant essential oil
Bacitracin 2-30 parts
3-40 parts of mandelic acid
10-55 parts of lactein
8-40 parts of oligosaccharide prebiotics.
By adopting the technical scheme, the medicinal effect is better by adopting the weight ratio, each component can play an obvious role, the medicine has very strong activity of inhibiting and killing pathogenic bacteria, fungi, spirochaetes, trichomonas, toxoplasma and viruses, can adjust the activity of endogenous probiotics (lactobacillus) of the Yin tract, maintain the acidic environment of the vagina, has a self-cleaning function and immunity, and nourishes the tissue cells of the vagina, the uterus and the ovary, thereby preventing the occurrence of vagina infectious diseases.
The invention is further configured to: the natural plant essential oil comprises one or two of rose essential oil and cananga odorata essential oil.
By adopting the technical scheme, the rose essential oil contains linalool, linalool formate, beta-citronellol, citronellol formate, citronellol acetate, geraniol, yak acid formate, geraniol acetate, phenethyl alcohol, nerol, 3-methyl-1-butanol, trans-beta-ocimene, pentadecane, 2-tridecanone, 1-pentanol, 1-ethanol, 3-vinyl ester, 3-vinyl acetate, benzyl alcohol, eugenol, methyl clove oil, 6-methyl-5-hepten-2-one, neral, yakenal, nerol acetate, geranylacetone, 2-undecanone, 2-tridecanone, 2-pentadecanone, tetradecanal, beta-phenethyl alcohol, Eugenol, methyl eugenol, acetic acid-beta-phenethyl alcohol ester, beta-damascone, rose oxide and alpha-threone. The flower also contains quercetin, cyanidin, organic acid, beta-carotene, fatty oil, etc.; can regulate female endocrine, nourish uterus and vagina, relieve dysmenorrhea, improve sexual cold feeling and climacteric discomfort, and can comprehensively promote female charm and delay aging after long-term use.
The cananga odorata essential oil contains linalool, geranyl acetate, caryophyllene (terpene), methyl benzoate, benzyl acetate, benzyl benzoate and other sesquiterpenes; can regulate reproductive system, and is effective for balancing female hormone, promoting estrus, improving sexual coldness and sexual impotence.
The essential oil has the effects of regulating endocrine, nourishing vaginal tissue cells and preventing vaginal aging, is beneficial to maintaining vaginal microecological balance and nourishing vaginal tissue cells, and further improves the treatment and nourishing effects of the invention.
The invention is further configured to: the natural essential oil comprises 5-25 parts of rhododendron anthopogonoides essential oil, 1-8 parts of clary sage essential oil, 3-11 parts of melaleuca viridis essential oil, 3-20 parts of artemisia scoparia essential oil, 3-8 parts of rose essential oil and 1-5 parts of ylang-ylang essential oil.
By adopting the technical scheme, the medicinal effect is better by adopting the above proportioning, the compatibility among the essential oils is better, and the synergistic effect is obvious.
The invention is further configured to: the disinfection essential oil milk also comprises 5-20 parts of emulsifier.
By adopting the technical scheme, through the emulsification of the emulsifier, the components are well mixed, and the prepared product is convenient to use.
The invention is further configured to: the emulsifier is one or two of RH-40 and Tween-60.
By adopting the technical scheme, RH-40 is a nonionic solubilizer and an emulsifier which are obtained by the mutual reaction of hydrogenated castor oil and ethylene oxide, the HLB value is 14-16, and the use concentration is relatively lower compared with other solubilizers. The invention can ensure that the components are mixed more uniformly, the product has better performance and does not generate side effect.
The Tween 60, also known as polysorbate 60 and polyoxyethylene sorbitan monostearate has the properties of wetting, foaming, diffusion and the like, and the HLB value is 14.9, so that the components can be mixed more uniformly by applying the Tween 60, the product performance is better, and no side effect is generated.
The invention is further configured to: the purity of the natural essential oil is more than 99%.
By adopting the technical scheme, the essential oil has high purity and better treatment effect, and is not easy to have other impurities to influence the uniform mixing of each component.
The invention is further configured to: the sterilized essential oil emulsion is in the form of emulsion, liniment or emulsion.
By adopting the technical scheme, the dosage forms are convenient to use, and the user experience is better. And the components therein are not adversely affected.
The second object of the present invention is to provide: a process for preparing the disinfecting oil emulsion for external use of woman features simple process, easy popularization, high curative effect and high activity to suppress and kill pathogenic bacteria, fungus, spirochete, trichomonad, toxoplasma and virus.
The second technical purpose of the invention is realized by the following technical scheme: a production process of female topical disinfectant essential oil emulsion is provided, and the produced essential oil emulsion has stable quality and convenient use.
A production process of female external disinfectant essential oil emulsion comprises the following steps of:
s1 natural essential oil to form phase A for later use;
s2, sequentially putting bacitracin, mandelic acid, lactein and oligosaccharide prebiotics into deionized water, heating to 37 ℃, and fully stirring until completely dissolving to obtain a mixed solution B for later use.
S3 adding emulsifier into phase B, mixing, heating to 37 deg.C, slowly adding phase A under stirring, and emulsifying to obtain essential oil emulsion.
By adopting the technical scheme, the production process is simple and easy to operate, all components are mixed more uniformly and quickly, the produced essential oil emulsion is stable in quality and convenient to use, the production time is saved, and the popularization and the production are facilitated. Experiments show that the essential oil emulsion prepared by the steps has better drug effect.
The invention is further configured to: the preparation steps of the natural essential oil in the S1 are that the plant is firstly distilled to obtain crude essential oil, then the crude essential oil is extracted to obtain corresponding secondary essential oil, and finally the secondary essential oil is fractionated and collected.
By adopting the technical scheme, purer essential oil can be obtained, the purity of the essential oil is high, and the treatment effect is better; the distillation process is relatively simple and is convenient to popularize.
The invention is further configured to: the emulsifying time in S3 is 6-24 hours.
By adopting the technical scheme, the essential oil emulsion coagulant with aromatic smell and stable properties can be prepared.
In summary, the present invention has the following advantageous features:
the novel, safe and efficient vaginal microecological preparation is developed according to the microecological principle of human bodies and is scientifically prepared from natural plant essential oil, a selective antibacterial agent, a microbial extract and prebiotics, and combines multiple effects of nourishing, eliminating harm, selectively resisting bacteria, maintaining vaginal microecological balance, nourishing vaginal tissue cells, regulating endocrine and resisting aging.
Secondly, the compound has strong activity of killing protozoa such as trichomonas, toxoplasma and the like, and greatly improves the treatment effect on trichomonas vaginitis.
And thirdly, the bactericide can efficiently kill or inactivate pathogens such as mould, Neisseria gonorrhoeae, treponema pallidum, HPV, HSV, HIV and the like, and prevent and treat various vaginal inflammations and adnexitis such as mycotic, bacterial and senile vaginitis, pelvic inflammation, pruritus vulvae, eczema, leukoplakia, cervical erosion, sexually transmitted diseases, viral infection and other gynecological infectious diseases.
Fourthly, maintaining the acid-base balance of vagina: the product has strong pH buffer capacity, can maintain and adjust the physiological state and self-cleaning effect of the environment pH of 3.5-4.5 in the vagina for a long time, and improves the resistance of the vagina.
Fifthly, maintaining private parts and keeping youth: the functional molecules of various natural essential oils are absorbed by the mucous membrane, nourish the uterus, the ovary and the vagina, regulate the internal secretion, improve the sexual indifference, the dyspareunia, the vaginal dryness and the climacteric discomfort, and can comprehensively promote the charm of women and delay the senility after long-term use.
Sixthly, safety: the pure plant microecological preparation has no irritation and no toxic and side effects.
Detailed Description
A female topical disinfectant essential oil emulsion, obtained by orthogonal experimental method in the following examples. In particular, see the following table:
wherein the natural essential oil emulsion comprises 10 parts of rhododendron anthopogonoides essential oil, 6 parts of clary sage essential oil, 8 parts of melaleuca alternifolia essential oil, 10 parts of artemisia scoparia essential oil, 4 parts of rose essential oil and 3 parts of ylang-ylang essential oil; in addition, 11 parts of an emulsifier was added.
Example 17
A female external disinfectant essential oil emulsion, example 17 is different from example 12 in that the natural essential oil emulsion comprises 5 parts of rhododendron anthopogonoides essential oil, 8 parts of clary sage essential oil, 3 parts of melaleuca viridis essential oil, 20 parts of artemisia scoparia essential oil, 8 parts of rose essential oil and 1 part of ylang essential oil; in addition, 5 parts of emulsifier is added.
Example 18
A female external disinfectant essential oil emulsion, example 18 is different from example 12 in that the natural essential oil emulsion comprises 25 parts of rhododendron anthopogonoides essential oil, 1 part of clary sage essential oil, 11 parts of melaleuca alternifolia essential oil, 3 parts of artemisia scoparia essential oil, 3 parts of rose essential oil and 1 part of ylang essential oil; in addition, 20 parts of emulsifier is added.
Example 19
A female external disinfectant essential oil emulsion, example 18 is different from example 12 in that the natural essential oil emulsion comprises 10 parts of rhododendron anthopogonoides essential oil, 3 parts of clary sage essential oil, 5 parts of melaleuca viridis essential oil, 3 parts of artemisia scoparia essential oil, 5 parts of rose essential oil and 2 parts of ylang essential oil; in addition, 8 parts of an emulsifier was added.
A preparation method of externally-applied disinfectant essential oil emulsion for women comprises the following steps:
s1 weighing rhododendron essential oil, clary sage essential oil, melaleuca alternifolia essential oil, artemisia pigweed essential oil, rose essential oil and cananga odorata essential oil according to parts by weight, and fully mixing to form phase A for later use;
s2, sequentially putting bacitracin, mandelic acid, lactein and oligosaccharide prebiotics into deionized water, heating to 37 ℃, and fully stirring until completely dissolving to obtain a mixed solution B for later use;
s3, selecting 1-2 of RH-40 and Tween-60 as emulsifiers to obtain a mixed solution C, adding 5-20 parts of the C into the B, mixing uniformly, heating to 37 ℃, slowly adding the A under stirring, emulsifying sufficiently for 6-24 hours to obtain the essential oil emulsion.
Wherein the natural essential oil in S1 is prepared by distilling plant to obtain crude essential oil, extracting the crude essential oil to obtain corresponding second-stage essential oil, and fractionating and collecting the second-stage essential oil, wherein the specific fractionation is to collect rhododendron anthopogonoide essential oil from rhododendron anthopogonoide second-stage essential oil; collecting artemisia pigweed essential oil from the artemisia pigweed secondary essential oil; collecting clary sage essential oil from the clary sage secondary essential oil; collecting melaleuca alternifolia essential oil from the melaleuca alternifolia secondary essential oil, and collecting rose essential oil from rose secondary essential oil; collecting cananga essential oil from cananga secondary essential oil; the purity of the collected essential oil is more than or equal to 99.99 percent.
Experimental study
The sterilization experiment of the essential oil emulsion prepared in the above example is carried out by the following specific experimental method.
Materials and methods
The test bacterial (worm) strains candida albicans ATCC 10231, staphylococcus aureus ATCC 25923, escherichia coli ATCC 25922 and lactobacillus acidophilus ATCC 314; trichomonas vaginalis clinical strain (3 strain); different target bacteria and insect strains are enriched by liquid broth, and logarithmic phase bacterial suspension and 12h insect strain culture suspension are taken as test bacteria (insect) strains. The essential oil emulsion prepared by the embodiment of the invention is respectively acted on tested bacteria (insect) strains for 1, 2 and 4 hours, after the medicines are removed, the tested bacteria are inoculated on test agar plates of various target bacteria, and are cultured for 48 to 72 hours at 35 ℃ to observe the results; the tested insect plants are directly observed for activity, granulation and insect body breakage rate by a high power microscope. Positive control (no drug group) and negative control (blank medium) were set up separately. The results show that the essential oil milk prepared in examples 1-19 has complete inhibition effect on lactobacillus acidophilus for 4 hours, and has no inhibition and killing effect after 1 and 2 hours, which indicates that the antibacterial effect on lactobacillus is weaker than that of pathogenic bacteria.
The microbial killing test of the essential oil emulsion comprises the following steps: the stock solution acts on escherichia coli for 10 minutes, the average killing rate is 100 percent, and acts on staphylococcus aureus for 15 minutes, and the average killing rate is 99.98 percent; acts on candida albicans for 15 minutes, and the average killing rate is 99.99 percent. After the essential oil emulsion is stored in an incubator at 37 ℃ for 90 days, the essential oil emulsion acts on escherichia coli for 10 minutes, and the average killing rate is 99.99%. Meets the regulation of GB15981-1995 standard (the killing rate is more than or equal to 99.9 percent).
The stock solution of the essential oil emulsion acts on lactobacillus acidophilus for 15 minutes, and the average killing rate is 43.20 percent; the detected result does not meet the regulation of GB15981-1995 standard (the killing rate is more than or equal to 99.9 percent).
The comprehensive effect of the example 12 in the above embodiment is better, the stock solution acts on escherichia coli for 7 minutes, the average killing rate is 100%, the stock solution acts on staphylococcus aureus for 10 minutes, and the average killing rate is 99.98%; acts on candida albicans for 12 minutes, and the average killing rate is 99.99 percent. After the essential oil emulsion is stored in an incubator at 37 ℃ for 90 days, the essential oil emulsion acts on escherichia coli for 8 minutes, and the average killing rate is 99.99%. Therefore, the essential oil emulsion prepared in the embodiment 12 is selected to be prepared into three dilutions of 1, 2 and 4 times of dilution, the dilution is respectively acted on the tested bacterium (insect) strain for 1, 2 and 4 hours, after the drug is removed, the tested bacterium is inoculated on test agar plates of various target bacteria, the test agar plates are cultured for 48 to 72 hours at the temperature of 35 ℃, and the result is observed; the tested insect plants are directly observed for activity, granulation and insect body breakage rate by a high power microscope. Positive control (no drug group) and negative control (blank medium) were set up separately. The experimental results are as follows;
note: the growth or non-growth of the plants with each action time after 48-72 h culture is expressed as 'growth' and 'non-growth',
"+" and "-" represent the presence or absence of growth of the target bacteria for each action time, respectively; mortality of the insect strain was expressed as%.
From the table above, it can be seen that the essential oil emulsion has complete inhibition or killing effect on 3 tested pathogenic bacteria in the stock solution with the test concentration and 2-fold dilution, and has 100% killing effect on trichomonas.
The above results demonstrate that the essential oil emulsions of the present invention have a selective killing effect on microorganisms. The vaginal antibacterial liquid has obvious killing effect on pathogenic bacteria (staphylococcus aureus, candida albicans and the like), and the killing rate of beneficial bacteria (lactobacillus) in the vagina does not meet the GB15981-1995 standard (the killing rate is more than or equal to 99.9 percent), namely the killing effect on the beneficial bacteria is ineffective.
3. The invention discloses an acute oral toxicity test of essential oil emulsion.
Materials and animals
1. The test object is the essential oil emulsion, and a sample is light brown condensed emulsion;
2. white mice of Kunming species, the weight of which is 18-22 g.
Second, method
1. The test is according to the acute oral toxicity test of 3.4 in the first minute volume of the third edition of the disinfection technical Specification;
2. test method, dose setting 20000mg/kg, taking 20 animals, each half of male and female, fasting the animals for 12 hours before gavage, gavage once, continuously observing for 14 days, and recording whether the animals have toxic symptoms and death conditions.
Thirdly, experimental results: the tested animals have no obvious toxic symptoms and no death during the observation period.
Fourthly, conclusion: under the experimental condition, the test object is judged to be actually nontoxic to the white mouse of the test animal through an oral toxicity test according to the acute toxicity LD50 dose grading standard.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments, and all technical solutions belonging to the idea of the present invention belong to the protection scope of the present invention. It should be noted that modifications and embellishments within the scope of the invention may occur to those skilled in the art without departing from the principle of the invention, and are considered to be within the scope of the invention.
Claims (10)
1. A female external use recuperation type sterilized essential oil emulsion is characterized by comprising the components of natural plant essential oil, bacitracin, mandelic acid, lactein and oligosaccharide prebiotics; wherein the natural plant essential oil comprises one or more of rhododendron anthopogonoides essential oil, clary sage essential oil, melaleuca viridis essential oil, and artemisia pigweed essential oil.
2. The female disinfectant essential oil emulsion for external use according to claim 1, which comprises the following components in parts by weight:
2-40 parts of natural plant essential oil
Bacitracin 2-30 parts
3-50 parts of mandelic acid
10-55 parts of lactein
8-50 parts of oligosaccharide prebiotics.
3. The female disinfectant essential oil emulsion for external use according to claim 1, which comprises the following components in parts by weight:
2-30 parts of natural plant essential oil
Bacitracin 2-30 parts
3-50 parts of mandelic acid
10-55 parts of lactein
And 8-20 parts of oligosaccharide prebiotics.
4. The female disinfectant essential oil emulsion for external use according to claim 1, which comprises the following components in parts by weight:
2-40 parts of natural plant essential oil
Bacitracin 2-30 parts
3-40 parts of mandelic acid
10-55 parts of lactein
8-40 parts of oligosaccharide prebiotics.
5. The female disinfectant essential oil emulsion for external use according to claim 1, wherein the natural plant essential oil further comprises one or two of rose essential oil and ylang-ylang essential oil.
6. The female disinfectant essential oil emulsion as claimed in claim 1, wherein the natural essential oil comprises 5-25 parts of rhododendron anthopogonoides essential oil, 1-8 parts of clary sage essential oil, 3-11 parts of melaleuca alternifolia essential oil, 3-20 parts of artemisia pigskin essential oil, 3-8 parts of rose essential oil and 1-5 parts of ylang essential oil.
7. The female disinfectant essential oil emulsion for external use according to claim 1, wherein the disinfectant essential oil emulsion further comprises 5-20 parts of an emulsifier.
8. The female disinfectant essential oil emulsion for external use according to claim 7, wherein the emulsifier is one or both of RH-40 and Tween-60.
9. A production process of female external disinfectant essential oil emulsion is characterized in that the preparation of the female external disinfectant essential oil emulsion of any one of claims 1 to 8 comprises the following steps:
s1 natural essential oil to form phase A for later use;
s2, sequentially putting bacitracin, mandelic acid, lactein and oligosaccharide prebiotics into deionized water, heating to 37 ℃, and fully stirring until completely dissolving to obtain a mixed solution B for later use;
s3 adding emulsifier into phase B, mixing, heating to 37 deg.C, slowly adding phase A under stirring, and emulsifying to obtain essential oil emulsion.
10. The process for producing female disinfectant essential oil emulsion as claimed in claim 9, wherein the natural essential oil in S1 is prepared by distilling plant to obtain crude essential oil, extracting the crude essential oil to obtain corresponding secondary essential oil, and fractionating and collecting the secondary essential oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810609051.2A CN110585418A (en) | 2018-06-13 | 2018-06-13 | External use disinfection essential oil emulsion for women and production process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810609051.2A CN110585418A (en) | 2018-06-13 | 2018-06-13 | External use disinfection essential oil emulsion for women and production process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110585418A true CN110585418A (en) | 2019-12-20 |
Family
ID=68849229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810609051.2A Pending CN110585418A (en) | 2018-06-13 | 2018-06-13 | External use disinfection essential oil emulsion for women and production process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110585418A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791242A (en) * | 2021-01-08 | 2021-05-14 | 西安贝迪斯可生物科技有限公司 | Oil-in-water lubricant containing prebiotics, preparation method thereof and condom |
| CN112972516A (en) * | 2021-02-25 | 2021-06-18 | 河南比福制药股份有限公司 | A disinfectant product for treating otitis externa |
| CN115192696A (en) * | 2022-07-13 | 2022-10-18 | 翔宇药业股份有限公司 | Active antibacterial gynecological lotion and preparation method thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416863A (en) * | 2002-11-06 | 2003-05-14 | 易寄东 | External medicine for treating dermatosis |
| CN1470250A (en) * | 2002-07-23 | 2004-01-28 | 陈秀枢 | External-use disinfecting medicinal preparation for women |
| CN102512490A (en) * | 2012-01-10 | 2012-06-27 | 唐嗣信 | Aromatherapy essential oil for treating gynecological inflammation and essential oil aromatherapy patch |
| CN105343591A (en) * | 2015-11-06 | 2016-02-24 | 阙剑波 | Essential oil for cleaning and caring female private parts and preparation method of essential oil |
| CN106665700A (en) * | 2016-12-07 | 2017-05-17 | 张树清 | Botanical disinfection composition, disinfectant and preparation method thereof |
| CN106692611A (en) * | 2017-01-11 | 2017-05-24 | 葛龙海 | Gynecological antibacterial solution |
| CN106880698A (en) * | 2017-02-17 | 2017-06-23 | 云南同方科技有限公司 | A kind of plants essential oil and preparation method for treating child's property vaginitis |
| CN106924657A (en) * | 2017-02-17 | 2017-07-07 | 云南同方科技有限公司 | A kind of plant essential oil composition and preparation method, application for treating senile vahinitis |
| CN107115476A (en) * | 2017-05-27 | 2017-09-01 | 广西茶仔龙林业科技发展有限公司 | A kind of Feminine care solution |
| CN107412477A (en) * | 2017-09-14 | 2017-12-01 | 王季兰 | gynecological medical bacteriostatic gel |
| CN108096396A (en) * | 2018-03-07 | 2018-06-01 | 西安璀璨生物科技有限责任公司 | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa |
-
2018
- 2018-06-13 CN CN201810609051.2A patent/CN110585418A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1470250A (en) * | 2002-07-23 | 2004-01-28 | 陈秀枢 | External-use disinfecting medicinal preparation for women |
| CN1416863A (en) * | 2002-11-06 | 2003-05-14 | 易寄东 | External medicine for treating dermatosis |
| CN102512490A (en) * | 2012-01-10 | 2012-06-27 | 唐嗣信 | Aromatherapy essential oil for treating gynecological inflammation and essential oil aromatherapy patch |
| CN105343591A (en) * | 2015-11-06 | 2016-02-24 | 阙剑波 | Essential oil for cleaning and caring female private parts and preparation method of essential oil |
| CN106665700A (en) * | 2016-12-07 | 2017-05-17 | 张树清 | Botanical disinfection composition, disinfectant and preparation method thereof |
| CN106692611A (en) * | 2017-01-11 | 2017-05-24 | 葛龙海 | Gynecological antibacterial solution |
| CN106880698A (en) * | 2017-02-17 | 2017-06-23 | 云南同方科技有限公司 | A kind of plants essential oil and preparation method for treating child's property vaginitis |
| CN106924657A (en) * | 2017-02-17 | 2017-07-07 | 云南同方科技有限公司 | A kind of plant essential oil composition and preparation method, application for treating senile vahinitis |
| CN107115476A (en) * | 2017-05-27 | 2017-09-01 | 广西茶仔龙林业科技发展有限公司 | A kind of Feminine care solution |
| CN107412477A (en) * | 2017-09-14 | 2017-12-01 | 王季兰 | gynecological medical bacteriostatic gel |
| CN108096396A (en) * | 2018-03-07 | 2018-06-01 | 西安璀璨生物科技有限责任公司 | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa |
Non-Patent Citations (2)
| Title |
|---|
| 三采文化: "《精油芳疗养生事典》", 30 September 2005, 汕头大学出版社 * |
| 屈娴: "《精油完全使用手册》", 31 August 2011, 江西科学技术出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791242A (en) * | 2021-01-08 | 2021-05-14 | 西安贝迪斯可生物科技有限公司 | Oil-in-water lubricant containing prebiotics, preparation method thereof and condom |
| CN112972516A (en) * | 2021-02-25 | 2021-06-18 | 河南比福制药股份有限公司 | A disinfectant product for treating otitis externa |
| CN112972516B (en) * | 2021-02-25 | 2022-05-10 | 河南比福制药股份有限公司 | A disinfectant product for treating otitis externa |
| CN115192696A (en) * | 2022-07-13 | 2022-10-18 | 翔宇药业股份有限公司 | Active antibacterial gynecological lotion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3039556C (en) | Use of 2-phenylethanol in combination with other antimicrobial agents for vagina | |
| JP5065246B2 (en) | Compositions and methods for regulating and maintaining the microflora of straw and the acidity of straw | |
| CN102470117B (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof | |
| US20130108599A1 (en) | Herbal Vaginal Compositions | |
| RU2536264C2 (en) | Topical dermal composition containing salt and sugar as active ingredients for preventing and treating vaginosis, and using it | |
| CN102697671B (en) | Bacterium and disease prevention wet wipe liquid medicament and preparation method thereof | |
| CN106176430A (en) | A kind of disposable foam type women bactericidal liquid and preparation method thereof | |
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| KR101651530B1 (en) | Cleanser for women's vagina using herb extract and method for manufacturing the same | |
| CN110585418A (en) | External use disinfection essential oil emulsion for women and production process thereof | |
| CN110090195A (en) | A kind of women secret nursing gel and preparation method thereof | |
| CN113081928A (en) | Plant bacteriostatic gel and preparation method and application thereof | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| Coppock | Bee products as nutraceuticals to nutraceuticals for bees | |
| CN109288889A (en) | A kind of antibacterial gynecological composition, gel and preparation method thereof | |
| CN105232526A (en) | Application of medicine containing catechin to preparation of antibacterial medicines | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| US5244885A (en) | Camomile extract having antimicrobial properties, process for its manufacture and its use | |
| AU2018248728B2 (en) | Natural composition for use in gynaecology | |
| CN105770682A (en) | Suppository for treating colpitis mycotica of pregnant women | |
| CN102755578A (en) | Washing liquid for treating gynecologic diseases and preparation method thereof | |
| CA2819632C (en) | Vaginal composition based on alkyl polyglucosides | |
| CN102743432B (en) | Application of patchouli oil in preparation of medicines used for treating colpitis | |
| CN106177274A (en) | A kind of conception control gel composition and preparation method thereof | |
| CN102697686B (en) | Female care solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191220 |
|
| RJ01 | Rejection of invention patent application after publication |